EAHAD
European Association for Haemophilia
and Allied Disorders

European Association for Haemophilia and Allied Disorders

Advancing Haemophilia Outcomes Across Europe

Annual Report 2025

www.eahad.org

Summary

03. President Foreword

05. EAHAD 2025 Congress

06. Strategic Partnerships and Advocacy

08. Governance & Organisational Development

10. EUHASS

11. Committee & Working Group Achievements

17. Research Grants & Fellowships

19. Communication Strategy

21. Membership

22. Finances

24. Organisational Structure

26. Acknowledgements

President Foreword

Dear friends and colleagues,

It is my pleasure to present the EAHAD 2025 Annual Report, highlighting a year of continued progress, growing collaboration and important achievements across our community. Together with the Executive Committee, our committees and working groups, and the EAHAD executive office team, we have continued to strengthen EAHAD's role in improving care for people with haemophilia and allied disorders throughout Europe.

Our **2025 Congress** in Milan, held from 4 to 7 February, welcomed nearly 2,200 delegates from more than 78 countries and once again demonstrated the strength, impact and scientific vitality of our field. The meeting delivered an outstanding and highly interactive programme, covering novel therapies, gene therapy, von Willebrand disease, ageing, joint health and the growing role of artificial intelligence in care. With a record **422 abstract submissions**, the Congress further reinforced EAHAD's position as a leading **multidisciplinary forum for global scientific exchange and clinical advancement.**

In 2025, **collaboration and advocacy** remained central to EAHAD's mission. We formalised Memoranda of Understanding with both the International Society on Thrombosis and Haemostasis and the World Federation of Hemophilia, strengthening important international partnerships and creating a stronger framework for future joint action in education, science and advocacy.

At a critical moment for the field, EAHAD also joined ISTH and WFH in issuing a joint **Call to Action on haemophilia gene therapy**, helping ensure that the voice of the European haemophilia community was clearly represented in wider international discussions on innovation, access and the future of treatment.

This year also marked important developments in **EAHAD's governance and organisational growth**. We established the EAHAD Nomination Committee, an important milestone in further strengthening transparency, fairness and structure in our leadership processes. We also launched the new Von Willebrand Disease Working Group, bringing together a distinguished network of experts to advance knowledge and collaboration in one of the most common yet complex inherited bleeding disorders. In parallel, EAHAD strengthened its operational capacity through the recruitment of two new Project Coordinators, reflecting the continued expansion of our activities and our commitment to supporting them with the right expertise and infrastructure.

Our committees and working groups continued to make important contributions throughout 2025, advancing guidance, education and collaboration across a wide range of topics, from nursing care and physiotherapy to gene therapy, women and girls with bleeding disorders, and rare platelet disorders. The EUHASS registry remained a cornerstone of EAHAD's scientific and safety-monitoring work, while the Coagulation Factor Variant Databases project also made strong progress.

Education and professional development remained a key priority in 2025. We've started the updating process of our cornerstone publication "**European Principles of Haemophilia Care**", with the goal to have a new, comprehensive version published by 2027. Through the EAHAD Academy and the continued efforts of our educational and scientific groups, new modules and resources were released across a wide range of topics. We also continued to invest in the future of the field through our research grants and fellowships programme.

As we look ahead, we remain committed to supporting a strong, connected and forward-looking professional community. I would like to warmly thank all EAHAD members, committee and working group leaders, partners, supporters and the office team for their dedication and contribution throughout the year. Together, we are continuing to advance knowledge, strengthen care and create meaningful impact for people living with haemophilia and allied disorders across Europe.

Sincerely,

Jan Blatny

EAHAD President 2024-2026

EAHAD Congress

The EAHAD 2025 Congress, held in Milan from 4 to 7 February, once again demonstrated the strength, reach and scientific vitality of the haemophilia and allied disorders community. Bringing together **nearly 2,200 delegates from more than 78 countries**, the Congress provided an outstanding forum for multidisciplinary exchange, showcasing advances in novel therapies, gene therapy, von Willebrand disease, ageing, joint health and the growing role of artificial intelligence in care.

Under the leadership of EAHAD **Congress President Prof. Flora Peyvandi**, the meeting delivered a rich and highly interactive programme that combined scientific excellence with practical relevance for daily clinical care.

The Congress also attracted a record **422 abstract submissions**, underlining both the growing international profile of EAHAD and the community's continued commitment to research and innovation.

Strategic Partnerships & Advocacy

Memorandum of Understanding with the World Federation of Hemophilia

In 2025, EAHAD formalised a Memorandum of Understanding with the World Federation of Hemophilia (WFH), reaffirming a shared commitment to advancing care, education and advocacy for people living with haemophilia and other bleeding disorders. The signing marked an important step in strengthening international collaboration and creating additional opportunities for aligned action across professional and patient communities.

The agreement was formalised in person in Vienna, with the support of the European Haemophilia Consortium. Beyond its symbolic importance, the MoU provides a framework for closer cooperation on areas of shared interest and reflects EAHAD's continued commitment to partnership-building that delivers practical value for the field.

Memorandum of Understanding with the International Society on Thrombosis and Haemostasis

EAHAD also signed a Memorandum of Understanding with the International Society on Thrombosis and Haemostasis (ISTH), further consolidating a relationship that has already produced strong scientific collaboration. This agreement reflects sustained dialogue and mutual commitment, and positions both organisations to work together more effectively in support of the bleeding disorders community.

> **Together, healthcare professionals and patients can engage in meaningful work that drives progress in care, education, and advocacy.**

The MoU with ISTH is particularly significant in light of the increasing need for coordinated expert leadership on emerging therapies, data generation, education and standards of care. It also recognises the value of building structured partnerships that preserve EAHAD's strong European identity while deepening its international scientific contribution.

Joint call to action on haemophilia gene therapy

In response to decisions by several pharmaceutical companies to pause, scale back or discontinue haemophilia gene therapy programmes, EAHAD joined ISTH and WFH in issuing an urgent Call to Action. The statement underscored the importance of sustained innovation, equitable access to all effective treatment options and continued engagement between industry, regulators, researchers, payers and the patient community.

By contributing to this joint position, EAHAD helped ensure that the voice of the European haemophilia community remained part of a broader international discussion at a critical moment for the field. This initiative highlighted EAHAD's role not only as a scientific association, but also as a credible and constructive stakeholder in wider policy and advocacy debates.

→ Click here to learn more

Governance and organisational development

Establishment of the EAHAD Nomination Committee

A major governance milestone in 2025 was the establishment of the EAHAD Nomination Committee. Created to support a fair, transparent and structured process for Executive Committee elections, the Committee strengthens EAHAD's governance framework and helps align leadership selection with the association's long-term strategic goals.

The Committee combines institutional continuity with broader representation. It includes the EAHAD Officers as permanent members, together with additional members appointed from EAHAD working groups and committees on the basis of their expertise and experience. The Committee evaluates candidates against clearly defined eligibility and assessment criteria, including commitment to EAHAD's mission, leadership potential, multidisciplinary collaboration, professional experience and active engagement in the haemophilia community.

Establishment of the Von Willebrand Disease Working Group

In 2025, EAHAD took an important step in strengthening its scientific and clinical activities through the establishment of the Von Willebrand Disease (vWD) Working Group. The new Working Group brings together a distinguished European network of healthcare professionals, laboratory scientists and researchers with recognised expertise in von Willebrand disease.

The Group has been established with the overarching aim of improving knowledge, fostering collaboration and strengthening clinical understanding of von Willebrand disease across Europe. Its work will focus on several key priorities, including increasing awareness of vWD among healthcare professionals and the wider public, improving understanding of the epidemiology and broader burden of the disease, and advancing knowledge of patient demographics and bleeding phenotypes. It will also support greater insight into laboratory characteristics and the genetic basis of vWD, while promoting discussion around treatment strategies and their impact on patient outcomes and quality of life.

Strengthening the EAHAD Team

EAHAD also strengthened its operational capacity during 2025 through the recruitment of **two new Project Coordinators.** These appointments reflect the continued expansion of EAHAD's activities and the association's commitment to investing in the people and structures needed to support its strategic ambitions.

Noa Kabera

Focus on accreditation and audit, gene therapy and EUHASS, supporting one of EAHAD's most important long-standing initiatives in surveillance and data collection.

Contacts

+32 483 19 11 89
noa.kabera@eahad.org

Isidora Laur Vukovic

Lead and oversee all Working Group activities, helping ensure stronger coordination, follow-up and delivery across the association's growing scientific portfolio, and supporting key initiatives and cornerstone projects.

Contacts

+32 489 99 35 60
isidora.laur.vukovic@eahad.org

EUHASS



EUHASS remained a cornerstone of EAHAD's scientific and safety-monitoring work in 2025. A key publication from the registry, "Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry", provided an important overview of how the treatment landscape has evolved over the last 15 years and how these changes are influencing inhibitor surveillance.

Drawing on reports from 97 centres between 2008 and 2022, the study documented major shifts in treatment practice, including the widespread uptake of emicizumab in severe haemophilia A and extended half-life FIX products in severe haemophilia B. The analysis showed that by 2022, 44% of severe haemophilia A previously untreated patients and 25% of previously treated patients were receiving emicizumab prophylaxis, while use of extended half-life recombinant FIX had become dominant in severe haemophilia B.

Importantly, the study also highlighted a marked reduction in observed inhibitor incidence in severe haemophilia A previously untreated patients, while drawing attention to the increasingly complex challenge of assessing inhibitor risk in a rapidly changing therapeutic environment. The publication reinforces the value of EUHASS as a unique European platform for longitudinal surveillance, safety monitoring and evidence generation at a time of profound therapeutic transition.

→ Access the publication

Committee & Working Group achievements

Nurses Committee

The EAHAD Nurses Committee continued to advance both education and standards of care in 2025. In collaboration with WFH, ISTH and Haemnet, the Committee contributed to a **practical webinar series** designed to strengthen nurses' research literacy and scientific participation. Topics included literature searching, qualitative research and the development of journal clubs, with the broader aim of supporting nurses to engage more actively in congresses, abstract writing and professional exchange.

→ Access the webinars

A major scientific output was the development of the **European Principles of Nursing Care for Persons with Inherited Bleeding Disorders**. Through a structured, multi-phase process involving ten roundtable meetings and broad multidisciplinary review, the Committee defined a clear framework for high-quality, person-centred nursing care across European haemophilia treatment centres. The final principles recognise nurses as core members of the multidisciplinary team and emphasise coordinated care, education, treatment management, support across life stages, perioperative care, genetic counselling and dedicated attention to the needs of women and girls.

→ Access the publication "European Principles of Nursing Care for Persons With Inherited Bleeding Disorders"

Physiotherapists Committee

The Physiotherapists Committee continued to highlight the importance of movement, rehabilitation and long-term musculoskeletal health in haemophilia care. In 2025, the Committee conducted two meet the author interviews:

- **Acute neuromuscular and perceptual responses to blood flow restriction exercise in adults with severe haemophilia: a pilot study**, Daniel C. Ogrezeanu
- **Exercise-based telerehabilitation for the management of chronic pain in people with severe haemophilia: a mixed-methods feasibility study**, Paul Mclaughlin

→ Access the interviews

The Committee also supported broader access to best practice by promoting the **translation of the clinical practice guideline for physiotherapy in haemophilia** into multiple languages. This work helps extend the reach of expert guidance across Europe and supports more consistent, high-quality physiotherapy care in different national settings.

→ Access the translations



Psychosocial Professionals Committee

The Psychosocial Professionals Committee had a particularly productive year, with important outputs focused on the **psychosocial dimensions of gene therapy and other novel therapies**. Through an interdisciplinary European roundtable involving psychologists, social workers, physicians, physiotherapists, patients, researchers and industry representatives, the Committee gathered expert and lived-experience input to identify the key psychosocial themes that need to be addressed before, during and after gene therapy.

This work demonstrated that psychosocial readiness, expectation management, coping with uncertainty, adjustment to change and support for families are central to successful care pathways. It also highlighted that the perception of treatment "failure" is deeply influenced by expectations and therefore requires careful, person-centred support. These insights fed into the development of a practical framework for psychosocial support around gene therapy.

→ Read the publication "Recommendations for Psychosocial Support during Gene Therapy: Results From an EAHAD Interdisciplinary Roundtable"

The Committee further expanded this work through the publication of a **broader psychological framework for psychosocial care during novel therapies in haemophilia.** By offering a structured model that can be adapted across treatment phases and levels of psychosocial need, this initiative provides a valuable foundation for comprehensive care design and for future European principles in this area. It also reinforces the message that innovation in treatment must be matched by innovation in supportive care.

→ Read the publication "Psychosocial Care During Novel Therapies in Haemophilia: A Psychological Framework

Accreditation and audit of haemophilia centres Working Group

Our Working Group continued to advance the accreditation and audit of haemophilia centres in 2025 through its pilot project combining on-site and online audit approaches for European Haemophilia Comprehensive Care Centres and European Haemophilia Treatment Centres. Pilot activities included an on-site and/or online audits in Brno, Frankfurt, Milan and Cologne and a split blind audit process involving centres in Milan and Cologne.

This work represents an important step towards strengthening quality assurance, benchmarking and continuous improvement across the European haemophilia care network. By testing different audit formats and refining the methodology, EAHAD is helping to build a robust and practical accreditation framework that can support

Gene Therapy Working Group

The Gene Therapy Working Group remained one of EAHAD's most active scientific groups in 2025, combining education, consensus-building and community engagement. Its **educational programme** included a webinar on the multidisciplinary hub-centre model for gene therapy in haemophilia, covering liver health, laboratory requirements and the nursing role in care delivery. A second webinar focused on durability in gene therapy, exploring long-term treatment effectiveness from clinical, mechanistic and patient perspectives.

→ Watch the webinar recordings

The Working Group also advanced knowledge-gathering across Europe through **surveys for healthcare professionals and people with haemophilia on gene therapy knowledge**, information sources and treatment considerations. To maximise accessibility, the patient survey was made available in 21 European languages in addition to English, enabling broader participation and more representative input from across the region.

A major scientific output was the publication on **qualification criteria for gene therapy in haemophilia**, which set out key requirements for the safe and effective delivery of gene therapy through a hub-and-spoke model. The paper highlighted the importance of accreditation, regulatory compliance, specialist expertise, clinical trial experience, standard operating procedures and close collaboration between administering and follow-up centres. This work is an important contribution to the development of safe infrastructure for gene therapy in Europe.

→ Read the publication

Women and Girls+ with Bleeding Disorders Working Group

The Women and Girls+ with Bleeding Disorders Working Group continued to address **long-standing evidence gaps and inequities in care**. In 2025, the group supported the translation of the **“Time to Talk: Period” booklet** into multiple languages, helping expand access to information for women and girls across Europe.

→ Access the translations

The group also contributed important work examining the participation of women in haemophilia clinical trials. Its analysis showed that women remain markedly underrepresented in interventional studies and that female-specific entry criteria and outcomes, particularly around menstruation and heavy menstrual bleeding, are still largely absent from trial design. The work makes a strong case for more inclusive research methodologies and for the meaningful integration of women’s lived experience into study design and outcome assessment.

By bringing attention to these structural shortcomings, the Working Group is helping to shift the field toward more equitable research and more evidence-based care for women and girls affected by bleeding disorders.

→ Read the publication “Are Women Welcome in Haemophilia Trials?”

Glanzmann Thrombasthenia Working Group

The Glanzmann Thrombasthenia Working Group delivered a substantial body of work in 2025, reflecting EAHAD’s commitment to rare bleeding disorders and to generating practical evidence in areas where guidance remains limited. The group published a hypothesis-generating study on the use of light transmission aggregometry to monitor platelet transfusion response in Glanzmann Thrombasthenia, helping clarify the limitations of current laboratory tools and identifying priorities for future research.

→ Read the publication “The use of light transmission aggregometry for monitoring platelet transfusion response in a small case cohort of Glanzmann thrombasthenia patients: a hypothesis-generating study“

It also published survey-based work on the management of preconception, pregnancy and childbirth in women with Glanzmann Thrombasthenia, as well as on broader European clinical practice in the management of the disorder. These studies revealed areas of emerging consensus, such as the importance of multidisciplinary counselling and aspects of perioperative care, while also exposing variation in access, antibody screening practices, platelet support and postpartum haemorrhage management.

→ Read the publication “International Practices in Managing Preconception, Pregnancy and Childbirth in Women With Glanzmann Thrombasthenia: A Survey From the European Association of Haemophilia and Allied Disorders (EAHAD)“

→ Read the publication “European Management of Glanzmann’s Thrombasthenia: A Survey of Current Clinical Practice“

In addition, the group contributed a case series and literature review on pregnancy and childbirth in Glanzmann thrombasthenia, offering valuable insight into reproductive health challenges and the complexity of care before, during and after pregnancy. Taken together, these outputs represent a significant strengthening of the evidence base in an ultra-rare disorder where international guidance is still evolving.

→ Read the publication “Management of pregnancy and childbirth in Glanzmann thrombasthenia: A case series and review“

Coagulation Factor Variant Databases

The Coagulation Factor Variant Databases project made major technical and scientific progress in 2025. A dedicated pilot site was made available to curators for extensive testing of search functionality, data display, editing tools and new variant entry processes, supporting a robust validation and quality assurance phase ahead of public release.

By mid-2025, the live version of the new database platform had been launched and the legacy database taken offline. Continuous refinements and feature improvements followed during the remainder of the year, reflecting an active, iterative development process shaped by expert curator input.

Preparatory work also advanced significantly for the planned addition of a three-gene fibrinogen database in early 2026. In parallel, curators for factor XIII and von Willebrand factor largely assembled their datasets for future inclusion, paving the way for an expansion of coverage from six to nine coagulation factors. Additional expert curators in fibrinogen and factor XIII were also invited to join the Steering Group, further strengthening the scientific governance of this important resource.

→ Access the Databases

Research Grants & Fellowships

EAHAD continued to invest directly in the next generation of scientific discovery and clinical innovation through its 2025 research grants and fellowship programme. Funding was allocated across established researchers, young researchers, allied health professionals and training fellowships, supporting projects that span fundamental science, imaging innovation, clinical algorithms, musculoskeletal health and real-world patient experience.

Established Researchers (€33,000)

Investigating the Extravascular Distribution and Hemostatic Potential of Factor IX Padua in Haemophilia B Mice

Yesim Dargaud

Proteogenomics of Factor V Proteoforms

Maartje van den Biggelaar

Young Researchers (€32,000)

Proteomic analysis for biomarker discovery for joint bleeding and joint health in people with haemophilia
Andrea Giachi

Innovative MRI approach for differentiating active vs. inactive synovial proliferation in haemophilia
Flora van Leeuwen

A novel evidence-based algorithm for von Willebrand disease subclassification
Ferdows Atiq

Allied Health Professionals (€20,000)

How does the use of novel therapeutics with enhanced haemostatic protection influence symptoms, decision-making processes and self-management when treating a bleed?
Paul McLaughlin

Training Fellow (€10,000)

Training placement from Sultan Ahmad Shah Medical Centre (Malaysia) to the Royal London Hospital (UK)
Dhamirah Nazihah

Through these awards, EAHAD continues to foster promising ideas, support early-career development and strengthen the multidisciplinary research ecosystem that underpins better care for people with haemophilia and allied disorders.

Communication Strategy

EAHAD's communication strategy is designed to strengthen its position as a leading scientific voice in haemophilia and allied bleeding disorders by combining education, digital innovation, and community engagement across Europe.

Key Pillar #1

EAHAD Academy

The EAHAD Academy is the **central hub for the Association's educational activities**, providing healthcare professionals with on-demand access to high-quality, multidisciplinary learning resources in the field of haemophilia and allied bleeding disorders.

Launched in 2023, the platform hosts a comprehensive range of content, including **e-learning modules, webinars, live educational events, congress recordings, and expert interviews**.

+2100
Visits

7
E-Learning Modules

5
Live Webinars

Top 5 Countries

- **UK**
- **Germany**
- **Belgium**
- **Italy**
- **France**

A hub for learning.
A driver for impact.

Modules released in 2025:

- Congenital Fibrinogen Deficiency
- Acquired Haemophilia A: Current state of art and future directions
- Improving Research Publications
- Inherited FVII Deficiency
- Non-surgical management of haemophiliac arthropathy
- Glanzmann Thrombasthenia
- Heavy Menstrual Bleeding in women with a VRCFD and psychosocial aspects

→ E-learning Modules

Key Pillar #2
EAHAD Podcast

EAHAD has successfully expanded its communication ecosystem through its podcast series, which has quickly become a valuable platform for **sharing expert insights and fostering dialogue within the haemophilia community**.

+1200
Streams and downloads

→ EAHAD Podcast

Key Pillar #3
Digital Engagement

Social media plays a key role in amplifying EAHAD's voice and increasing engagement with its audience. Through platforms such as LinkedIn, Bluesky and X, EAHAD shares scientific updates, educational content, event highlights, and expert perspectives.

64000
Impressions on LinkedIn

1600
Reactions on LinkedIn

+699
New Followers on LinkedIn

48200
Impressions on X

3300
Engagements on X

Top Performing Posts



Membership

Membership in EAHAD is open to all healthcare professionals, including physicians, nurses, physiotherapists, psychosocial professionals, clinical scientists, and medical and scientific professionals employed in pharma who are working in the area of haemophilia and allied disorders.

199	Ordinary Members
54	Allied Health Professional Members
28	Junior Members
62	Associate Members
5	Honorary Members
348	**Total Members**

Finances

Income	Budget 2025 (€)
Annual Corporate Partner Support	200,000.00
EAHAD Congress Recovery	100,000.00
EAHAD Congress Profit	300,000.00
Membership Income	6,500.00
EUHASS Project Funding	390,000.00
Gene Therapy Working Group Funding	150,000.00
Total	**1,146,500.00**

Expenses	Budget 2025 (€)
Staff costs	153,000.00
Operational costs	100,000.00
Website maintenance and IT Support for all the projects	170,000.00
Total	**423,000.00**

Project Costs	Budget 2025 (€)
EAHAD Academy	20,000.00
Executive Committee	10,000.00
Nurses Committee	10,000.00
Psychosocial Committee	10,000.00
Coagulation Factor Variant Databases Steering Group Activities	30,000.00
Very Rare Coagulation Factor Deficiencies Working Group	10,000.00
Joint Health Working Group	10,000.00
Glanzmann’s Thrombasthenia Working Group	10,000.00
E-learning Working Group	10,000.00
Women and Girls+ with Bleeding Disorders Working Group	10,000.00
Gene Therapy Activities	150,000.00
Haemophilia Centre Certification and Audit	50,000.00
Research Grants	200,000.00
Communications costs	2,000.00
Haemophilia Journal subscriptions for members	6,500.00
EUHASS	160,000.00
Additional scientific initiatives	10,000.00
Total	**723,500.00**

Summary	Budget 2025 (€)
Total Income	1,146,500.00
Less Expenses	423,000.00
Less Project Costs	723,500.00
Total	**0.00**

Organisational Structure

Executive Committee	
Jan Blatny	President
Ana Boban	Vice President
Robert Klamroth	Past President
Niamh O'Connell	Treasurer
Wolfgang Miesbach	Secretary
Maria Teresa Alvarez Roman	Member
Fariba Baghaei	Member
Pratima Chowdary	Member
Samantha Gouw	Member
Maj Friberg Birkedal	Nurses Committee Chair and representative
Ruth Elise Dybvik Matlary	Physiotherapists Committee Chair and representative
Christina Burgess	Psychosocial Professionals Chair and representative

Staff	
Angelos Athanasopoulos	Chief Executive Officer
Giuliana Giardina	Communications and Events Lead
Isidora Laur Vukovic	Project Coordinator
Noa Kabera	Project Coordinator

Our activities are supported by a multitude of Committees and Working Groups:

- **Nomination Committee**
- **Nurses Committee**
- **Physiotherapists Committee**
- **Psychosocial Professionals Committee**
- **Coagulation Factor Variant Databases Steering Group**
- **Gene Therapy Working Group**
- **Haemophilia Centre Accreditation & Audit Working Group**
- **Women and Girls+ with Bleeding Disorders Working Group**
- **E-Learning Working Group**
- **Glanzmann Thrombasthenia Working Group**
- **Joint Health in Inherited Bleeding Disorders Working Group**
- **Very Rare Coagulation Factor Deficiencies Working Group**
- **Von Willebrand Disease Working Group**
- **EUHASS Steering Committee**

Acknowledgements

Funding

In 2025 we received funding for our **Congress** from:

BIOMARIN
CSL Behring
Kedrion Biopharma
Roche
novo nordisk
octapharma
Pfizer
sanofi
sobi rare strength
Spark THERAPEUTICS
Takeda

In 2025, we received **Corporate Support** from:

BIOMARIN
CSL Behring
HEMAB
Roche
novo nordisk
octapharma
Pfizer
sanofi
sobi rare strength
Takeda

In 2025, we received funding for our **EUHASS** activities from:

BAYER
BIOMARIN
Kedrion Biopharma
CSL Behring
novo nordisk
octapharma
Pfizer
Roche
sanofi
sobi rare strength
Takeda

Partners

EAHAD collaborates with the following organisations:

eha
EHC european haemophilia consortium
ISTH International Society on Thrombosis and Haemostasis
WFH WORLD FEDERATION OF HEMOPHILIA

Service providers

EAHAD works in cooperation with a number of companies that provide valuable services in order to make our work possible:

- **MCI Suisse** for our Congress organisational support
- **5 O'Clock** for administrative and bookkeeping support
- **Medical Data Solution & Services** for IT support
- **BOFIDI Accountants and Advisors** for accounting support
- **BOFIDI Legal** for legal support
- Dr **Peter Milanov** for his work on the EAHAD Gene Therapy Clinical Trials Database

Contact

European Association for Haemophilia and Allied Disorders (EAHAD) AISBL
Registration Number (BE): 0718.594.509

Cours Saint Michel, 30B
Securex Building/Hive5
1040 Brussels, Belgium

info@eahad.org

www.eahad.org